McDougle, Christopher J.
Thom, Robyn P.
Ravichandran, Caitlin T.
Palumbo, Michelle L.
Politte, Laura C.
Mullett, Jennifer E.
Keary, Christopher J.
Erickson, Craig A.
Stigler, Kimberly A.
Mathieu-Frasier, Lauren
Posey, David J.
Funding for this research was provided by:
Autism Speaks (#5717, #5717)
Article History
Received: 19 July 2021
Revised: 7 February 2022
Accepted: 8 February 2022
First Online: 3 March 2022
Competing interests
: Dr. McDougle is a consultant to Precidiag, Receptor Life Sciences, and Sage Therapeutics, and receives royalties from Oxford University Press and Springer Publishing. Dr. Thom receives research support from Precidiag. Dr. Palumbo receives research support from Otsuka Pharmaceuticals. Dr. Keary serves on the advisory board and receives research support from Ovid Therapeutics. Dr. Erickson is a consultant to Autifony, Stalicla, Scitoto Bioscience, Impel, and Confluence Pharmaceuticals. He is an inventor on patents describing methods of treatment in neurodevelopmental disorders held by the Cincinnati Children’s Hospital Research Foundation. Drs. Ravichandran and Politte, Ms. Mullett, Dr. Stigler, Ms. Mathieu-Frasier, and Dr. Posey have no disclosures or conflicts of interest to report.